Posts by: Alice Melão

News

Eureka Therapeutics is planning a Phase 1/2 clinical trial in the United States to explore the safety and effectiveness of its investigational T-cell therapy ET140202 in patients with advanced hepatocellular ... Read more

January 16, 2019

AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies

News

AbbVie and Tizona Therapeutics are partnering to develop immunotherapies that could reshape the tumor microenvironment and enhance immune responses against cancer cells. The agreement is intended to develop new CD39-targeted ... Read more

December 18, 2018

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

News

SELLAS Life Sciences announced plans for a newly streamlined Phase 3 trial to evaluate its investigational vaccine galinpepimut-S (GPS) as maintenance therapy for high-risk acute myeloid leukemia (AML) patients. If trial ... Read more

December 7, 2018December 7, 2018

BioLineRx‘s Immunotherapy AGI-134 Receives FDA’s Biological Product Designation

News

The U.S. Food and Drug Administration has granted BioLineRx’s investigational immunotherapy AGI-134 a biological product designation, making the company eligible for 12-year market exclusivity after the treatment is approved in the ... Read more

November 20, 2018November 20, 2018

Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs of Efficacy in Advanced Colorectal Cancer

News

CYAD-01 — Celyad‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to ... Read more

November 13, 2018November 13, 2018

FDA Approves Keytruda-Chemotherapy Combo as First-line Therapy for NSCLC

News

Keytruda (pembrolizumab) can now be used in combination with chemotherapy — Paraplatin (carboplatin) plus Taxol (paclitaxel) or Abraxane (nab-paclitaxel) — as first-line therapy for patients with metastatic squamous non-small cell lung cancer (NSCLC) ... Read more

November 7, 2018November 7, 2018

CHMP Favors EU Approval of Keytruda for Advanced Melanoma Patients with Complete Tumor Resection

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) for the treatment of advanced melanoma patients ... Read more

October 30, 2018October 30, 2018

Opdivo Fails to Extend Survival in SCLC Patients in Phase 3 Trial, Bristol-Myers Squibbs Reports

News

Bristol-Myers Squibb‘s immune checkpoint inhibitor Opdivo (nivolumab) is no better than standard chemotherapy at extending the lives of patients with small cell lung cancer (SCLC) who failed prior platinum-based chemotherapy, ... Read more

October 23, 2018October 23, 2018

OSE Seeks French Regulatory Approval for Phase 2 Trial of Tedopi in Advanced Pancreatic Cancer

News

OSE Immunotherapeutics is planning to launch a Phase 2 clinical trial to evaluate the potential of its Tedopi vaccine, alone and in combination with Opdivo (nivolumab), as a maintenance treatment for ... Read more

October 19, 2018

Celyad, Horizon Discovery Group Working to Develop New CAR T-cell Therapies

News

A recent collaboration between Celyad and Horizon Discovery Group hopes to develop new off-the-shelf CAR T-cell therapies using Horizon’s short hairpin RNA (shRNA) platform. This will be Celyad’s second non-gene-edited donor-derived platform. Standard ... Read more